Adverum Biotechnologies

atai Life Sciences Strengthens Board with Appointment of Two New Independent Directors

Retrieved on: 
星期四, 五月 23, 2024
Allergan, Allscripts, Rachel Haurwitz, University, Therapy, Drug development, Jennerex, Trevena Inc, Adverum Biotechnologies, Cornell University, Summit Health, Laurent, Pharmaceutical industry

NEW YORK and BERLIN, May 23, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced the appointment of Scott Braunstein, M.D., and Laurent Fischer, M.D., as independent directors of atai’s supervisory board (“Board”) subject to applicable legal requirements.

Key Points: 
  • NEW YORK and BERLIN, May 23, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced the appointment of Scott Braunstein, M.D., and Laurent Fischer, M.D., as independent directors of atai’s supervisory board (“Board”) subject to applicable legal requirements.
  • He is an operating partner at Aisling Capital and serves on the Board of Directors at both Caribou Biosciences, Inc. and Trevena Inc.
  • Laurent Fischer, M.D., is the CEO and President of Adverum Biotechnologies and serves on the Board of Directors at Mirum Pharmaceuticals, Inc., Lycia Therapeutics and Teal.
  • Christian Angermayer, Founder and Chairman of atai, said: “I am thrilled to welcome Scott and Laurent to atai’s Board.

Adverum Biotechnologies Reports First Quarter 2024 Financial Results and Provides Pipeline Highlights

Retrieved on: 
星期四, 五月 9, 2024
Adverum Biotechnologies, FDA, AMD, Patient, Inflammation, Retinitis, Investment, Safety, CST, Research, Chorioretinitis, Compensated emancipation, Vascular occlusion, Employment, Macula, Episcleritis, Data, OPTIC, Three Months, Vasculitis, Society, LUNA, Intraocular pressure, VEGF, ASRS, Injection, Pharmaceutical industry

REDWOOD CITY, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases, today reported financial results for the first quarter of 2024. The company also provided recent pipeline highlights.

Key Points: 
  • “Our presentation will feature a 26-week landmark interim analysis, which is expected to serve as the basis of our FDA end-of-Phase 2 meeting.
  • The award was granted under the Adverum Biotechnologies, Inc. 2017 Inducement Plan, as amended and restated, and will vest over four years, subject to continued service with Adverum.
  • Stock-based compensation expense included in research and development expenses was $1.1 million for the first quarter of 2024.
  • Stock-based compensation expense included in general and administrative expenses was $3.0 million for the first quarter of 2024.

Adverum Biotechnologies to Participate in Upcoming May Investor Conferences

Retrieved on: 
星期五, 五月 3, 2024
Bank of America, Webcast, Conference, Adverum Biotechnologies

BofA Securities 2024 Health Care Conference on Wednesday, May 16, 2024 at 3:40 p.m. PT.

Key Points: 
  • BofA Securities 2024 Health Care Conference on Wednesday, May 16, 2024 at 3:40 p.m. PT.
  • H.C. Wainwright 2nd Annual BioConnect Investor Conference on Monday, May 20, 2024 at 11:00 a.m.
  • The on-demand webcast of the panel discussion may be accessed under Events and Presentations in the Investors section of Adverum’s website.
  • A replay of the webcast will be available on the website for at least 30 days following the presentation.

Adverum Biotechnologies to Present LUNA 26-week Phase 2 Interim Analysis at the ASRS Annual Scientific Meeting

Retrieved on: 
星期四, 四月 25, 2024
News, ASRS, Society, Adverum Biotechnologies, LUNA

REDWOOD CITY, Calif., April 25, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that the company will present the 26-week landmark interim analysis from its ongoing LUNA Phase 2 study of ixoberogene soroparvovec (Ixo-vec) for the treatment of wet age-related macular degeneration (wet AMD) at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting being held in Stockholm, Sweden from July 17 - 20, 2024.

Key Points: 
  • REDWOOD CITY, Calif., April 25, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that the company will present the 26-week landmark interim analysis from its ongoing LUNA Phase 2 study of ixoberogene soroparvovec (Ixo-vec) for the treatment of wet age-related macular degeneration (wet AMD) at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting being held in Stockholm, Sweden from July 17 - 20, 2024.
  • Title: Ixoberogene Soroparvovec (Ixo-vec) IVT Gene Therapy for Neovascular AMD: First-Time 26-Week Interim Analysis Results From the Phase 2 LUNA Study
    The presentation will be available on the News and Publications section of Adverum’s website shortly after the presentation.

US Retinal Specialists Highlight the Greatest Opportunity for Gene Therapies

Retrieved on: 
星期二, 三月 19, 2024
Retina, Stargardt disease, Macular edema, Retinitis pigmentosa, Eye, Intelligence, Paratriathlon, Hope, Stargardt, Adverum Biotechnologies, Safety, NAMD, Geographic atrophy, Ophthalmology, Diabetic retinopathy, Medical device

Unlike other organs, the eye's compact size and accessibility have made it an ideal application for gene therapies, offering targeted treatment with minimal systemic impact.

Key Points: 
  • Unlike other organs, the eye's compact size and accessibility have made it an ideal application for gene therapies, offering targeted treatment with minimal systemic impact.
  • As advancements continue, a plethora of gene therapies for retinal disorders are on the horizon.
  • Spherix Global Insights collaborated with 77 retinal specialists to understand their perspectives on adopting gene therapies, specifically where specialists were and were not willing to use gene therapy across diseases and patient types.
  • While retinal specialists express eagerness for gene therapies, dissatisfaction towards current treatments like Syfovre and Izervay underscores the need for innovation.

Adverum Biotechnologies Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Pipeline Highlights and Corporate Updates

Retrieved on: 
星期一, 三月 18, 2024
Research, Adverum Biotechnologies, Vasculitis, Three Months, Macula, Chorioretinitis, Inflammation, Patient, Episcleritis, American Academy, Anti-VEGF, LUNA, Intraocular pressure, Investment, Clinical trial, Injection, Safety, Drug development, Paratriathlon, AMD, AAO, OPTIC, Retinitis, CST, Vascular occlusion, Annual general meeting, VEGF, Pharmaceutical industry

REDWOOD CITY, Calif., March 18, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases, today reported financial results for the fourth quarter and full year 2023. The company also provided recent pipeline highlights and corporate updates.

Key Points: 
  • The company also provided recent pipeline highlights and corporate updates.
  • 85% and 68% of patients at the 2E11 and 6E10 doses, respectively, received no supplemental injections through 26 weeks.
  • Stock-based compensation expense included in research and development expenses was $1.0 million for the fourth quarter of 2023.
  • Stock-based compensation expense included in general and administrative expenses was $3.1 million for the fourth quarter of 2023.

Adverum Biotechnologies to Participate in the TD Cowen 44th Annual Health Care Conference

Retrieved on: 
星期三, 二月 28, 2024
Adverum Biotechnologies, Conference, Webcast

REDWOOD CITY, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that Laurent Fischer, M.D., president and chief executive officer of Adverum Biotechnologies, will participate in the Ophthalmology Corporate Panel Discussion at the TD Cowen 44th Annual Health Care Conference on Tuesday, March 5th, 2024 at 9:10 a.m.

Key Points: 
  • REDWOOD CITY, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that Laurent Fischer, M.D., president and chief executive officer of Adverum Biotechnologies, will participate in the Ophthalmology Corporate Panel Discussion at the TD Cowen 44th Annual Health Care Conference on Tuesday, March 5th, 2024 at 9:10 a.m.
  • ET.
  • The on-demand webcast of the panel discussion may be accessed under Events and Presentations in the Investors section of Adverum’s website.
  • A replay of the webcast will be available on the website for at least 30 days following the presentation.

Seek Labs Welcomes Cindy Dunkle, Accomplished HR Leader with Extensive Life Sciences Experience, to Board of Directors

Retrieved on: 
星期二, 二月 27, 2024
Health, Infectious Diseases, Other Science, Research, Science, Pharmaceutical, Biotechnology, Therapy, Acquisition, Week, CRISPR, Poverty, Seek, Metropolitan, Management, IPO, Metropolitan State University, Safety, Genentech, Environmental health, Patient, Adverum Biotechnologies, Woman

Dunkle brings decades of life sciences leadership experience and connections that will enhance Seek Labs’ strategic direction and employee-centered approach.

Key Points: 
  • Dunkle brings decades of life sciences leadership experience and connections that will enhance Seek Labs’ strategic direction and employee-centered approach.
  • Dunkle is widely recognized for her profound understanding of human capital management in the life sciences sector.
  • Jared Bauer, CEO, expressed his enthusiasm to have Dunkle join Seek Labs’ Board: “We are thrilled to have Cindy Dunkle join our Board of Directors.
  • "I am honored to join Seek Labs’ Board of Directors at a pivotal moment as the company continues to grow and expand its footprint in the life sciences and biotechnology industry,” said Cindy Dunkle.

Adverum Biotechnologies to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Retrieved on: 
星期一, 二月 12, 2024
Adverum Biotechnologies, Conference, Webcast

REDWOOD CITY, Calif., Feb. 12, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that Laurent Fischer, M.D., president and chief executive officer of Adverum Biotechnologies, will present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference on Tuesday, February 13th, 2024 at 12:00 p.m.

Key Points: 
  • REDWOOD CITY, Calif., Feb. 12, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that Laurent Fischer, M.D., president and chief executive officer of Adverum Biotechnologies, will present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference on Tuesday, February 13th, 2024 at 12:00 p.m.
  • ET.
  • The on-demand webcast corporate presentation may be accessed under Events and Presentations in the Investors section of Adverum’s website.
  • A replay of the webcast will be available on the website for at least 30 days following the presentation.

Adverum Biotechnologies Announces Positive Preliminary Efficacy and Safety Data from LUNA Phase 2 Trial of Ixo-vec in Patients with Wet AMD

Retrieved on: 
星期四, 二月 8, 2024
Chorioretinitis, Injection, Principal, Inflammation, Life, Adverum Biotechnologies, VEGF, AMD, Partner (business rank), Vasculitis, Patient, Safety, Paratriathlon, Prednisone, University of Nevada, Reno, Intraocular pressure, Data, Webcast, University, Retinitis, M.A, Clinical research, CST, Vascular occlusion, Pharmaceutical industry

These data are being presented by Dr. Arshad Khanani today at the 47th Annual Meeting of the Macula Society.

Key Points: 
  • These data are being presented by Dr. Arshad Khanani today at the 47th Annual Meeting of the Macula Society.
  • “Wet AMD is a leading cause of blindness in people over the age of 65, requiring life-long anti-VEGF injections.
  • Our goal with Ixo-vec is to provide patients virtually injection-free management of their wet AMD lasting years and potentially for life,” stated Laurent Fischer, M.D., president and chief executive officer of Adverum Biotechnologies.
  • The LUNA trial builds on our experience with the OPTIC study, where landmark 2-year data was recently published in The Lancet’s eclinicalmedicine.